Harrow Health Inc (HROW) saw its stock surge 5.04% in the pre-market session on Wednesday, following positive topline results from the Phase 3 clinical trial of MELT-300, a non-opioid sedative drug being developed by Melt Pharmaceuticals, a company spun off from Harrow in 2019.
The Phase 3 study evaluated the safety and efficacy of MELT-300, a sublingual tablet combining midazolam and ketamine, for procedural sedation during cataract surgery. The results demonstrated that MELT-300 was statistically superior to both sublingual midazolam and placebo in providing successful sedation, with a favorable safety profile comparable to placebo.
According to Melt Pharmaceuticals CEO Larry Dillaha, these positive results support a potential regulatory submission to the FDA for MELT-300's approval. If approved, MELT-300 could offer a safe and effective non-IV, non-opioid alternative to current IV-based sedation protocols involving opioids for cataract surgeries, which are expected to exceed 5 million annually in the coming years in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.